Eli Lilly Strikes Up to $1.5B Deal to Buy Calytrix Bio
Eli Lilly agrees to acquire Calytrix Bio in a deal worth up to $1.5 billion, expanding its pipeline through another targeted biotech buy.
Eli Lilly agrees to acquire Calytrix Bio in a deal worth up to $1.5 billion, expanding its pipeline through another targeted biotech buy.
EV startup chiefs say they're not waiting on Washington to revive federal support, even if Democrats make midterm gains.
OpenAI launched an AI payments wallet inside ChatGPT, letting autonomous agents make purchases through major card networ…
CNBC's latest NHL franchise valuations show the average team is now worth $2.71 billion, a sharp 23% surge from last yea…
One concise briefing, weekly. No spam.
By subscribing you agree to receive periodic communications. Unsubscribe anytime via the link in each message or our Unsubscribe page.